002581.SZ
*ST未名
SZSE · Healthcare · C 制造业 · CN
CNY 5.21
−10.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 283.3M | 274.8M | 360.4M | 429.8M | 357.1M |
| Cost of Revenue | 160.4M | 129.6M | 72.9M | 83.4M | 76.2M |
| Gross Profit | 122.9M | 145.2M | 287.5M | 346.4M | 280.9M |
| Operating Expenses | |||||
| R&D Expense | 18.1M | 18.9M | 25.4M | 59.8M | 27.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 137.3M | 129.9M | 83.2M | 165.0M | 133.7M |
| Selling & Marketing Expense | 107.4M | 139.5M | 253.4M | 288.3M | 292.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 266.5M | 291.4M | 364.1M | 527.3M | 467.3M |
| Cost and Expenses | 426.9M | 421.0M | 437.0M | 610.7M | 543.5M |
| Operating Income (EBIT) | (187.0M) | (179.0M) | (111.5M) | (293.4M) | 33.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (183.8M) | (175.5M) | (146.2M) | (313.2M) | 12.7M |
| Income Tax Expense | (14.6M) | (14.7M) | (3.3M) | 8.9M | 13.6M |
| Bottom Line | |||||
| Net Income | (133.7M) | (116.3M) | (137.3M) | (332.5M) | (14.7M) |
| Earnings from Cont. Ops | (169.2M) | (160.8M) | (142.8M) | (322.1M) | (858.7K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (133.7M) | (116.3M) | (137.3M) | (332.5M) | (14.7M) |
| Per Share | |||||
| Basic EPS | (CN¥0.20) | (CN¥0.18) | (CN¥0.21) | (CN¥0.50) | (CN¥0.02) |
| Diluted EPS | (CN¥0.20) | (CN¥0.18) | (CN¥0.21) | (CN¥0.50) | (CN¥0.02) |
| Revenue Per Share | CN¥0.43 | CN¥0.42 | CN¥0.55 | CN¥0.65 | CN¥0.54 |
| Shares | |||||
| Basic Shares Outstanding | 659.7M | 659.6M | 659.8M | 659.8M | 658.3M |
| Diluted Shares Outstanding | 659.7M | 659.6M | 659.8M | 659.8M | 658.3M |
| Profitability Metrics | |||||
| EBITDA | — | (141.2M) | (69.2M) | (220.6M) | 101.2M |
| D&A | — | 37.7M | 42.2M | 72.8M | 67.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026